CGRP receptor antagonists (gepants).

Q2 Medicine Handbook of clinical neurology Pub Date : 2024-01-01 DOI:10.1016/B978-0-12-823357-3.00033-1

Samaira Younis, Nina V Latysheva, Alexey B Danilov, Messoud Ashina

引用次数: 0

Abstract

Small molecule calcitonin gene-related peptide (CGRP) receptor antagonists are commonly referred to as gepants. The first generation of gepants provided the first line of evidence of CGRP-mediated antimigraine medication in 2004-2011. However, further development was halted due to either lack of oral availability or concerns of hepatotoxicity. More than 15 years later, the first second generation of gepants, ubrogepant and rimegepant, are now approved for the acute treatment of migraine with or without aura. Furthermore, a novel and promising third-generation gepant, zavegepant, has recently been approved as well. In this chapter, we review the evidence supporting the effectiveness, safety, and tolerability of gepants for the acute treatment of migraine. Furthermore, we discuss the potential limitations and future directions of this class of migraine-specific medication.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

CGRP 受体拮抗剂（gepants）。

小分子降钙素基因相关肽（CGRP）受体拮抗剂通常被称为 gepants。2004-2011 年，第一代 gepants 提供了 CGRP 介导的抗偏头痛药物的第一线证据。然而，由于缺乏口服可用性或担心肝毒性，进一步的开发工作被迫停止。15 年后的今天，第一代第二代抗偏头痛药物--乌洛格潘和瑞美格潘，已被批准用于有先兆或无先兆偏头痛的急性治疗。此外，一种新型且前景广阔的第三代格潘（zavegepant）最近也获得了批准。在本章中，我们将回顾支持开喷剂用于偏头痛急性期治疗的有效性、安全性和耐受性的证据。此外，我们还讨论了这类偏头痛特效药的潜在局限性和未来发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Handbook of clinical neurology Medicine-Neurology (clinical)

CiteScore

4.10

自引率

0.00%

发文量

302

期刊介绍： The Handbook of Clinical Neurology (HCN) was originally conceived and edited by Pierre Vinken and George Bruyn as a prestigious, multivolume reference work that would cover all the disorders encountered by clinicians and researchers engaged in neurology and allied fields. The first series of the Handbook (Volumes 1-44) was published between 1968 and 1982 and was followed by a second series (Volumes 45-78), guided by the same editors, which concluded in 2002. By that time, the Handbook had come to represent one of the largest scientific works ever published. In 2002, Professors Michael J. Aminoff, François Boller, and Dick F. Swaab took on the responsibility of supervising the third (current) series, the first volumes of which published in 2003. They have designed this series to encompass both clinical neurology and also the basic and clinical neurosciences that are its underpinning. Given the enormity and complexity of the accumulating literature, it is almost impossible to keep abreast of developments in the field, thus providing the raison d''être for the series. The series will thus appeal to clinicians and investigators alike, providing to each an added dimension. Now, more than 140 volumes after it began, the Handbook of Clinical Neurology series has an unparalleled reputation for providing the latest information on fundamental research on the operation of the nervous system in health and disease, comprehensive clinical information on neurological and related disorders, and up-to-date treatment protocols.

期刊最新文献

5-HT1F agonists. Biobehavioral treatments of migraine. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. CGRP receptor antagonists (gepants). Comorbidities of migraine: Sleep disorders.